Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Tyrosine kinase inhibitors (TKIs) target key signaling pathways in hematologic malignancies.
• These pathways are also crucial for normal immune cell function.
• The COVID-19 pandemic prompted investigation into TKIs for managing immune complications.

Purpose of the Study:

• To analyze the impact of major TKIs on immune regulation.
• To provide a rationale for using TKIs in diseases like COVID-19.
• To understand TKI effects beyond hematologic malignancies.

Main Methods:

• Review of in vitro studies on TKI effects on immune cells.
• Analysis of clinical observations, considering limitations of animal models and patient populations.
• Focus on specific TKIs: Bruton's tyrosine kinase, spleen tyrosine kinase, BCR-Abl, PI3K/mTOR, JAK/STAT, and FLT3 inhibitors.

Main Results:

• TKIs exhibit diverse, class-specific effects on immune cells due to nonoverlapping target affinities.
• In vitro data and limited in vivo observations suggest significant immunomodulatory potential.
• Understanding these effects is crucial for predicting clinical outcomes.

Conclusions:

• TKIs approved for hematologic malignancies have complex immunomodulatory effects.
• These effects warrant consideration for managing immune dysregulation in infectious diseases like COVID-19.
• Further research is needed to fully elucidate in vivo TKI impacts on the immune system.